EP3976001A4 - Formulations de comprimés d'aprémilast - Google Patents
Formulations de comprimés d'aprémilast Download PDFInfo
- Publication number
- EP3976001A4 EP3976001A4 EP20813638.2A EP20813638A EP3976001A4 EP 3976001 A4 EP3976001 A4 EP 3976001A4 EP 20813638 A EP20813638 A EP 20813638A EP 3976001 A4 EP3976001 A4 EP 3976001A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- apremilast
- tablet formulations
- formulations
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/08440A TR201908440A2 (tr) | 2019-05-31 | 2019-05-31 | Apremi̇lastin tablet formülasyonlari |
PCT/TR2020/050318 WO2020242414A1 (fr) | 2019-05-31 | 2020-04-15 | Formulations de comprimés d'aprémilast |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3976001A1 EP3976001A1 (fr) | 2022-04-06 |
EP3976001A4 true EP3976001A4 (fr) | 2023-04-26 |
Family
ID=73553856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20813638.2A Pending EP3976001A4 (fr) | 2019-05-31 | 2020-04-15 | Formulations de comprimés d'aprémilast |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3976001A4 (fr) |
TR (1) | TR201908440A2 (fr) |
WO (1) | WO2020242414A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4183389A1 (fr) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Composition pharmaceutique comprenant de l'aprémilast |
CN114533691A (zh) * | 2022-03-21 | 2022-05-27 | 成都百裕制药股份有限公司 | 一种阿普米司特片剂及其工业化制备方法 |
CN116531326B (zh) * | 2023-04-26 | 2023-11-14 | 广东嘉博制药有限公司 | 一种阿普米司特的口服乳剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017083348A1 (fr) * | 2015-11-11 | 2017-05-18 | Celgene Corporation | Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10774042B2 (en) * | 2016-05-12 | 2020-09-15 | Zaklady Farmaceutyczne Polpharma Sa | Crystalline forms of apremilast |
CN107115310A (zh) * | 2017-04-12 | 2017-09-01 | 广州艾格生物科技有限公司 | 一种阿普斯特口服固体制剂及其制备方法 |
US20200330433A1 (en) | 2017-10-10 | 2020-10-22 | Mankind Pharma Ltd. | Extended release pharmaceutical composition of apremilast |
-
2019
- 2019-05-31 TR TR2019/08440A patent/TR201908440A2/tr unknown
-
2020
- 2020-04-15 WO PCT/TR2020/050318 patent/WO2020242414A1/fr unknown
- 2020-04-15 EP EP20813638.2A patent/EP3976001A4/fr active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017083348A1 (fr) * | 2015-11-11 | 2017-05-18 | Celgene Corporation | Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations |
Also Published As
Publication number | Publication date |
---|---|
WO2020242414A1 (fr) | 2020-12-03 |
EP3976001A1 (fr) | 2022-04-06 |
TR201908440A2 (tr) | 2020-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3582755A4 (fr) | Préparations | |
EP3509581A4 (fr) | Formulations de (r | |
EP4045480A4 (fr) | Formulations pharmaceutiques | |
EP3860585A4 (fr) | Compositions thérapeutiques | |
EP3976001A4 (fr) | Formulations de comprimés d'aprémilast | |
EP3853204A4 (fr) | Compositions pharmaceutiques d'aprémilast améliorées et stables | |
EP3851121A4 (fr) | Composition pharmaceutique contenant un anticorps monoclonal anti-il-33 humain | |
EP3917910A4 (fr) | Composés et compositions thérapeutiques | |
EP3873444A4 (fr) | Composés et compositions thérapeutiques | |
EP3868371A4 (fr) | Nouvelle composition pharmaceutique | |
EP3755376A4 (fr) | Formulations contenant des protéases affectant la mucine | |
EP3716766A4 (fr) | Composés de benzoxaborole et leurs formulations | |
EP4007590A4 (fr) | Formulations comprenant du dihydrohonokiol | |
EP3886820B8 (fr) | Formulations de capsules | |
EP3873446A4 (fr) | Composés et compositions thérapeutiques | |
EP3881841A4 (fr) | Composition pharmaceutique | |
EP3810137A4 (fr) | Formulations de nitroimidazole | |
EP3810118A4 (fr) | Formulations de tegavivint et composés apparentés | |
EP3836920A4 (fr) | Formules d'ag10 | |
EP3817744A4 (fr) | Formes d'ivosidénib et compositions pharmaceutiques | |
EP3582748A4 (fr) | Formulations sans sulfate | |
EP3554508A4 (fr) | Formulations pharmaceutiques de suvorexant | |
EP4013441A4 (fr) | Formulations de larazotide | |
EP3801532A4 (fr) | Préparations de raltégravir | |
EP3984549A4 (fr) | Composition médicinale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211129 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230323 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/28 20060101ALI20230317BHEP Ipc: A61P 19/02 20060101ALI20230317BHEP Ipc: A61K 31/4035 20060101ALI20230317BHEP Ipc: A61K 9/20 20060101AFI20230317BHEP |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230708 |